Opium (Opioid) Addiction - Pipeline Review, H2 2012

Opium (Opioid) Addiction – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Opium (Opioid) Addiction - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Opium (Opioid) Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction. Opium (Opioid) Addiction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Opium (Opioid) Addiction.
- A review of the Opium (Opioid) Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Opium (Opioid) Addiction pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Opium (Opioid) Addiction Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Opium (Opioid) Addiction 10
Opium (Opioid) Addiction Therapeutics under Development by Companies 12
Opium (Opioid) Addiction Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Opium (Opioid) Addiction Therapeutics – Products under Development by Companies 20
Opium (Opioid) Addiction Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Opium (Opioid) Addiction Therapeutics Development 22
Nanotherapeutics, Inc. 22
Catalyst Pharmaceutical Partners, Inc. 23
Mundipharma International Limited 24
Titan Pharmaceuticals, Inc. 25
Orexo AB 26
Camurus AB 27
Omeros Corporation 28
KYORIN Pharmaceutical Co., Ltd. 29
TheraQuest Biosciences, LLC 30
Opium (Opioid) Addiction – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
NanoBUP - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ibudilast - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
vigabatrin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
OX-219 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
lofexidine hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Lofexidine + Marinol - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CPP-115 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
buprenorphine hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
morphine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Memantine + Buprenorphine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Memantine + Vivitrol - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Diamorphine + Methadone - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
naltrexone - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pioglitazone - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
OMS-403 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Methadone + Dextromethorphan - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Methadone + Memantine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
tramadol hydrochloride ER - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
memantine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
buprenorphine hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
buprenorphine hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Buprenorphine + Gabapentin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
naltrexon ER - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
morphine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
FP-004 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Hydromorphone Hydrochloride + Buprenorphine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Opium (Opioid) Addiction Therapeutics – Drug Profile Updates 70
Opium (Opioid) Addiction Therapeutics – Discontinued Products 81
Opium (Opioid) Addiction Therapeutics - Dormant Products 82
Opium (Opioid) Addiction – Product Development Milestones 83
Featured News & Press Releases 83
Aug 21, 2012: Orexo Reports Successful Achievement Of Product Stability Data For Opioid Dependence Drug OX219 83
Jul 23, 2012: Orexo Reports Positive Feedback From Pre-NDA Meeting With FDA Over Opioid Dependency Drug 83
Jul 02, 2012: Orexo Completes Bioavailability Study Of OX219 Ahead Of Schedule 84
Jun 19, 2012: Orexo Successfully Completes OX219 Dose Proportionality Study Ahead Of Schedule 85
Jun 07, 2012: Catalyst Pharma To Present CPP-115 Progress At 2012 College On Problems Of Drug Dependence Symposium 85
May 03, 2012: Orexo Presents Plans To Accelerate Development Of OX219 86
Apr 20, 2012: Titan Pharma To Present Phase III Probuphine Data At ASAM 43rd Medical-Scientific Conference 87
Feb 28, 2012: BioDelivery Sciences And FDA Reach Agreement On BNX Development Plan 87
Feb 09, 2012: Titan Pharmaceuticals Announces Positive Results Of Six-Month Open-Label Safety Retreatment Study Of Probuphine 88
Dec 20, 2011: BioDelivery Sciences Announces Confirmation Of Final Formulation Of BEMA Buprenorphine/Naloxone Based On Positive BNX-102 Study 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Tables
Number of Products Under Development for Opium (Opioid) Addiction, H2 2012 10
Products under Development for Opium (Opioid) Addiction – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
Nanotherapeutics, Inc., H2 2012 22
Catalyst Pharmaceutical Partners, Inc., H2 2012 23
Mundipharma International Limited, H2 2012 24
Titan Pharmaceuticals, Inc., H2 2012 25
Orexo AB, H2 2012 26
Camurus AB, H2 2012 27
Omeros Corporation, H2 2012 28
KYORIN Pharmaceutical Co., Ltd., H2 2012 29
TheraQuest Biosciences, LLC, H2 2012 30
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 36
Opium (Opioid) Addiction Therapeutics – Drug Profile Updates 70
Opium (Opioid) Addiction Therapeutics – Discontinued Products 81
Opium (Opioid) Addiction Therapeutics – Dormant Products 82

List of Figures
Number of Products under Development for Opium (Opioid) Addiction, H2 2012 10
Products under Development for Opium (Opioid) Addiction – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Discovery and Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Route of Administration, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Molecule Type, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 36

- Nanotherapeutics, Inc.
- Catalyst Pharmaceutical Partners, Inc.
- Mundipharma International Limited
- Titan Pharmaceuticals, Inc.
- Orexo AB
- Camurus AB
- Omeros Corporation
- KYORIN Pharmaceutical Co., Ltd.
- TheraQuest Biosciences, LLC